| Literature DB >> 30819052 |
Brenda Maldonado-Arriaga1,2, Noé Escobar-Escamilla3, Juan Carlos Pérez-Razo4, Sofia Lizeth Alcaráz-Estrada4, Ignacio Flores-Sánchez5, Daniel Moreno-García5, Rebeca Pérez-Cabeza de Vaca1, Paul Mondragón-Terán1, Jonathan Shaw6, Cecilia Hernandez-Cortez7, Graciela Castro-Escarpulli2, Juan Antonio Suárez-Cuenca1.
Abstract
Entities:
Keywords: Mollicutes; Mycoplasma; antimicrobial resistance profile; bacterial isolate; infertility; reproductive abnormalities
Year: 2019 PMID: 30819052 PMCID: PMC7140224 DOI: 10.1177/0300060519828945
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Demographic and clinical characteristics of couples with infertility.
| Men(n = 37) | Women(n = 37) | p value | |
|---|---|---|---|
| Age (years) | 34.7 ± 0.21 | 31.5 ± 1.4 | N.S. |
| Start of sexual life < 18 years | 12 (32.4) | 5 (13.5) | 0.04 |
| Number of previous sexual partners | |||
| 1–2 | 5 (13.5) | 18 (48.6) | |
| 3–4 | 17 (45.9) | 14 (37.8) | 0.001 |
| ≥5 | 16 (43.2) | 5 (13.5) | |
| Genitourinary symptoms | |||
| Symptomatic* | 11 (29.7) | 28 (75.7) | <0.001 |
| Asymptomatic | 26 (70.3) | 9 (24.3) | |
| Years of infertility# | |||
| <5 years | 29 (78.3) | <0.001 | |
| ≥5 years | 8 (21.6) | ||
Quantitative data are shown as mean ± standard deviation. Qualitative data are shown as number (%). #Determined by the number of couples. Statistical analysis was performed with Fisher’s test. *Symptomatic was considered as any combination of secretion, itching, and/or burning when urinating.
Figure 1.Characterization of clinical specimens. Left panels: bacteria growing in pleuropneumonia-like organism medium. (a) Mycoplasma hominis shows a characteristic “fried egg” shape. (b) Ureaplasma urealyticum shows a “sea urchin” shape. Right panels: Biochemical characterization using the Mycoplasma IST2 kit. The first three domes on the left are intended for identification purposes. The next two domes are intended for quantification purposes. The last nine domes are intended for characterization of antibiotic resistance, according to color development: yellow (susceptible) or red (resistant).
Ureaplasma urealyticum and Mycoplasma hominis antimicrobial profile of all samples.
| Antimicrobial | S | R | S | R | S | R |
|---|---|---|---|---|---|---|
| Doxycycline | 15 (100) | 0 (0) | 2 (100) | 0 (0) | 4 (100) | 0 (0) |
| Tetracycline | 3 (20) | 12 (80) | 0 (0) | 2 (100) | 2 (50) | 2 (50) |
| Josamycin | 15 (100) | 0 (0) | 2 (100) | 0 (0) | 2 (50) | 2 (50) |
| Erythromycin | 13 (86.6) | 2 (13.3) | 0 (0) | 2 (100) | 2 (50) | 2 (50) |
| Azithromycin | 13 (86.6) | 2 (13.3) | 0 (0) | 2 (100) | 0 (0) | 4 (100) |
| Clarithromycin | 14 (93.3) | 1 (6.66) | 0 (0) | 2 (100) | 0 (0) | 4 (100) |
| Ofloxacin | 3 (20.0) | 12 (80.0) | 0 (0) | 2 (100) | 0 (0) | 4 (100) |
| Ciprofloxacin | 2 (13.3) | 13 (86.6) | 0 (0) | 2 (100) | 0 (0) | 4 (100) |
| Pristinamycin | 15 (100) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) |
Qualitative data are shown as number (%). Samples included were individual and mixed cervicovaginal and urethral samples.
Clinical condition associated with genital mycoplasma infection (n = 37).
| AS* | AZ* | OL | OL-1 | TO# | PRM# | EP# | NCE | C | |
|---|---|---|---|---|---|---|---|---|---|
|
| 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (16.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
|
| 5 (55.5) | 2 (22.2) | 0 (0) | 0 (0) | 8 (66.6) | 8 (66.6) | 5 (41.6) | 1 (8.3) | 1 (8.3) |
| 0 (0) | 0 (0) | 1 (11.1) | 1 (11.1) | 2 (16.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Data are shown as number (%). The symbols indicate conditions associated with infection of genital mycoplasmas in men (*) and women (#), p < 0.001. AS, asthenospermia; AZ, azoospermia; OL, oligoasthenozoospermia; OL1, oligoasthenoteratozoospermia; TO, tubular obstruction; EP, ectopic pregnancy; PRM, premature rupture of the membranes; NCE, nonspecific chronic endocervicitis; C, cervicitis; U., Ureaplasma; M., Mycoplasma.
Antimicrobial resistance profile and genital abnormalities.
With genital abnormalities | Without genital abnormalities | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||||||
| S | R | S | R | S | R | S | R | S | R | S | R | |
| Doxycycline | – | – | – | – | – | – | 15 (100) | 0 (0) | 2 (100) | 0 (0) | 4 (100) | 0 (0) |
| Tetracycline | 3 (20) | 12 (80) | – | – | – | – | – | – | 0 (0) | 2 (100) | 2 (50) | 2 (50) |
| Josamycin | – | – | – | – | – | – | 15 (100) | 0 (0) | 2 (100) | 0 (0) | 2 (50) | 2 (50) |
| Erythromycin | – | – | 0 (0) | 2 (100) | – | – | 13 (86.6) | 2 (13.3) | – | – | 2 (50) | 2 (50) |
| Azithromycin | – | – | 0 (0) | 2 (100) | 0 (0) | 4 (100) | 13 (86.6) | 2 (13.3) | – | – | – | – |
| Clarithromycin | – | – | 0 (0) | 2 (100) | 0 (0) | 4 (100) | 14 (93.3) | 1 (6.66) | – | – | – | – |
| Ofloxacin | 3 (20.0) | 12 (80.0) | 0 (0) | 2 (100) | 0 (0) | 4 (100) | – | – | – | – | – | – |
| Ciprofloxacin | 2 (13.3) | 13 (86.6) | 0 (0) | 2 (100) | 0 (0) | 4 (100) | – | – | – | – | – | – |
| Pristinamycin | – | – | – | – | – | – | 15 (100) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) |
Qualitative data are shown as number (%). Samples included were individual and mixed cervicovaginal and urethral samples. U., Ureaplasma; M., Mycoplasma; S, sensitive; R, resistant.